Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Cagrilintide is an investigational long-acting amylin analog developed by Novo Nordisk, distinct from the GLP-1 class
- Phase 2 monotherapy at 2.4 mg weekly produced approximately 10% weight loss (Lau et al., The Lancet 2021)
- Best known as part of CagriSema, the combination with semaglutide; REDEFINE-1 phase 3 reported approximately 22.7% weight loss at 68 weeks
- Cagrilintide is not FDA-approved as of May 2026; FormBlends does not sell, supply, or compound it
- The amylin pathway is complementary to GLP-1 signaling, which is why combination therapy is the focus of Novo's development program
Direct answer
Cagrilintide is an investigational long-acting amylin analog from Novo Nordisk. It is not a GLP-1 medication; it works through the amylin and calcitonin receptors, a separate pathway from GLP-1. In phase 2 monotherapy at 2.4 mg weekly, cagrilintide produced approximately 10% weight loss. It is best known as part of the CagriSema combination with semaglutide, which is being developed for greater weight loss than either drug alone. Cagrilintide is not FDA-approved, and FormBlends does not sell or supply it.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Amylin, the hormone you have not heard of
- How cagrilintide works in plain terms
- The discovery story: from pramlintide to cagrilintide
- Phase 2 monotherapy data: Lau et al. 2021
- The CagriSema combination program
- Where cagrilintide fits in the obesity drug landscape
- Side effects and tolerability
- Regulatory status and timeline
- The contrary view: questions about CagriSema's added value
- Decision framework for patients interested in amylin
- FAQ
- Sources
Amylin, the hormone you have not heard of
Amylin is a 37-amino-acid peptide hormone secreted by pancreatic beta cells alongside insulin. When you eat, beta cells release both insulin (which regulates glucose uptake) and amylin (which regulates the appetite and satiety side of the eating process).
Amylin acts on several systems:
- Stomach: slows gastric emptying, prolonging the feeling of fullness
- Brain (area postrema, hypothalamus): enhances satiety signaling and reduces food intake
- Glucagon suppression: reduces post-meal glucagon release, contributing to glucose control
The hormone was identified in the 1980s during research on pancreatic islet pathology in type 2 diabetes. Amylin deposits (islet amyloid) accumulate in the pancreas of patients with type 2 diabetes, and researchers worked out what the soluble form of the hormone did.
Natural amylin has properties that make it difficult to use as a drug. It is highly insoluble at physiological pH (tends to aggregate into amyloid). It has a short half-life. It is unstable in solution. Drug developers have engineered modified versions that retain biological activity but are easier to formulate and dose.
The first pharmaceutical amylin analog was pramlintide, approved by the FDA in 2005 as Symlin for use in type 1 and type 2 diabetes. Pramlintide requires injection before each meal (three times daily), which limits adherence. Symlin has had modest commercial success.
Cagrilintide is the long-acting successor.
How cagrilintide works in plain terms
Cagrilintide binds the same family of receptors as natural amylin: the amylin receptor (a heterodimer of calcitonin receptor and receptor activity-modifying proteins) and, with weaker affinity, the calcitonin receptor itself.
Activation of these receptors produces three main effects:
Slowed gastric emptying. Food moves out of the stomach more slowly, prolonging mechanical and hormonal signals of fullness. This is the mechanism most patients notice subjectively: meals "stick around" longer, and the urge to eat between meals is reduced.
Enhanced central satiety signaling. Amylin receptors in the area postrema of the brainstem and the hypothalamus modulate appetite-regulating circuits. The effect overlaps partially with GLP-1 signaling but acts through different neural pathways. The combined effect when both are activated is greater than either alone.
Glucagon suppression. Amylin signaling reduces post-meal glucagon release from pancreatic alpha cells. This contributes to modest improvements in glucose control, especially after meals.
Cagrilintide does not affect insulin secretion directly. This is a key difference from GLP-1 receptor agonists, which enhance glucose-dependent insulin secretion. Cagrilintide's metabolic benefit is more weight-focused than glucose-focused.
The discovery story: from pramlintide to cagrilintide
Novo Nordisk acquired the amylin program through its acquisition of Amylin Pharmaceuticals' obesity-relevant intellectual property. Amylin Pharmaceuticals had developed pramlintide and was working on long-acting follow-on molecules before being acquired by Bristol-Myers Squibb in 2012; the obesity program eventually moved to Novo Nordisk through subsequent licensing or asset transfer.
Novo's chemistry team designed cagrilintide to extend the half-life of amylin from minutes to days. The key modifications:
- Substitution of selected amino acids to improve solubility and prevent aggregation
- Addition of a fatty acid linker that binds albumin in the bloodstream, similar to the technology used in semaglutide
- Structural changes that resist enzymatic degradation
The fatty acid albumin-binding strategy is the same approach Novo used with semaglutide. The albumin association serves as a slow-release depot, dramatically extending half-life. Cagrilintide's half-life in clinical studies is approximately 7 days, supporting once-weekly subcutaneous dosing.
This stable, long-acting amylin analog opened the door to once-weekly amylin therapy and to combination with weekly GLP-1 medications. The CagriSema combination was the obvious next step.
Phase 2 monotherapy data: Lau et al. 2021
The pivotal monotherapy data for cagrilintide comes from a phase 2 trial published by Lau and colleagues in The Lancet in 2021.
Trial design:
- 706 adults with BMI 30+ or BMI 27+ with comorbidities
- 26-week duration
- Cagrilintide doses: 0.3, 0.6, 1.2, 2.4, 4.5 mg weekly
- Comparator: placebo and liraglutide 3.0 mg daily
Key results:
| Treatment | Mean weight loss at 26 weeks |
|---|---|
| Placebo | ~3% |
| Cagrilintide 0.3 mg | ~6% |
| Cagrilintide 0.6 mg | ~6.8% |
| Cagrilintide 1.2 mg | ~7.4% |
| Cagrilintide 2.4 mg | ~10.1% |
| Cagrilintide 4.5 mg | ~10.8% |
| Liraglutide 3.0 mg | ~9.0% |
The 2.4 mg dose became the focus dose for subsequent development. The 4.5 mg dose produced only marginally more weight loss with possibly more side effects, suggesting diminishing returns at higher doses.
Cross-trial comparison: cagrilintide 2.4 mg monotherapy (~10% at 26 weeks) is roughly comparable to liraglutide 3.0 mg daily (~9% at 26 weeks) and below semaglutide 2.4 mg weekly (which produced ~14.9% over 68 weeks in STEP 1). On a pure weight-loss-per-week basis, cagrilintide and semaglutide are roughly comparable.
The Lau et al. paper is the most-cited cagrilintide source and the basis for "2.4 mg" being the most-quoted dose. This dose is what subsequent CagriSema trials have used.
The CagriSema combination program
The CagriSema program tests cagrilintide combined with semaglutide as a single fixed-dose product, administered as one weekly subcutaneous injection. The mechanistic rationale: GLP-1 signaling and amylin signaling are complementary, so combining them should produce greater weight loss than either alone.
Phase 2 data published by Enebo et al. in The Lancet 2021 showed CagriSema 2.4 mg + 2.4 mg produced approximately 15.7% weight loss at 20 weeks in adults with type 2 diabetes. The phase 3 REDEFINE-1 trial (Novo readout late 2024) reported approximately 22.7% mean weight loss at 68 weeks in patients with obesity without diabetes.
The 22.7% figure is notable. It sits between semaglutide (Wegovy, ~14.9%) and tirzepatide (Zepbound, ~22.5%). The CagriSema combination roughly matches tirzepatide on weight loss, with a different mechanism (GLP-1 + amylin) and a different combination strategy (fixed-dose vs single-molecule dual agonist).
However, REDEFINE-1's specific outcomes have been the subject of analysis. The Novo readout fell somewhat short of pre-trial market expectations, in part because:
- The control arm (semaglutide alone) achieved higher weight loss in REDEFINE-1 than in earlier STEP trials, narrowing the apparent CagriSema advantage
- Trial population differences influenced absolute numbers
- Investor expectations had built to anticipate CagriSema exceeding tirzepatide, which the data did not clearly support
Novo's subsequent CagriSema phase 3 trials (REDEFINE-2, REDEFINE-3, REDEFINE-4) are still underway or in analysis as of May 2026.
Where cagrilintide fits in the obesity drug landscape
| Drug | Mechanism | Format | Weight loss (top dose, in trials) | Status |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 monoagonist | Injection, weekly | ~14.9% (STEP 1) | FDA-approved |
| Zepbound (tirzepatide) | GLP-1/GIP dual | Injection, weekly | ~22.5% (SURMOUNT-1) | FDA-approved |
| Cagrilintide (monotherapy) | Amylin analog | Injection, weekly | ~10% at 26 weeks (Lau 2021) | Investigational |
| CagriSema | GLP-1 + amylin | Injection, weekly | ~22.7% (REDEFINE-1, 68 weeks) | Investigational |
| Retatrutide | GLP-1/GIP/glucagon | Injection, weekly | ~24% phase 2 (Jastreboff 2023) | Investigational |
| Orforglipron | GLP-1 small molecule | Oral, daily | ~14.7% (ACHIEVE-1) | Investigational |
Cagrilintide monotherapy alone is unlikely to be commercialized given the broader trend toward combination therapy and dual/triple agonists. The clinical and commercial focus is on CagriSema, where the combination produces results comparable to tirzepatide.
Side effects and tolerability
The amylin class shares some side effects with GLP-1 medications but also has class-specific concerns.
Common side effects of cagrilintide (from Lau et al. 2021 and subsequent CagriSema trials):
- Nausea: 30-40% at higher doses (similar to GLP-1 medications)
- Vomiting: 10-20%
- Diarrhea: 10-15%
- Decreased appetite: 10-15%
- Injection site reactions: 5-10%
The nausea profile in amylin medications has historically been a meaningful tolerability constraint. Pramlintide (the older amylin analog) had a high discontinuation rate due to nausea, partly because of dose-related effects. Cagrilintide appears to have somewhat better tolerability due to slow dose titration over multiple weeks.
A specific concern with amylin agents is hypoglycemia when combined with insulin. Pramlintide carries a boxed warning for this. Cagrilintide labeling, if approved, will likely include similar precautions for patients on concurrent insulin therapy.
Long-term safety data on cagrilintide is still limited. The drug has not had extensive post-marketing experience. Patients should expect labeling to evolve as more data accumulate.
Regulatory status and timeline
Cagrilintide is investigational as of May 2026. No major regulator has approved it as a standalone medication or as part of the CagriSema combination.
Novo's regulatory strategy appears to focus on CagriSema rather than cagrilintide monotherapy. The REDEFINE-1 readout (late 2024) was positive but not as strong as some analysts had expected. Novo has indicated continued development and filing for CagriSema, with a regulatory timeline that is still being clarified.
Timeline expectations (speculative):
- CagriSema filing: possibly in 2025-2026 pending full REDEFINE program data
- FDA decision: plausibly in 2026-2027
- Cagrilintide monotherapy: unclear if Novo will pursue this indication separately
Patients should not plan around specific approval dates. Regulatory timelines slip, and the REDEFINE-1 results have raised some open questions about competitive positioning that Novo is still navigating.
The contrary view: questions about CagriSema's added value
The bullish CagriSema thesis: combining two complementary mechanisms produces additive weight loss, with greater efficacy than either drug alone. The market case is that CagriSema matches or exceeds tirzepatide using a different mechanism, giving Novo a competitive product.
Several critiques of this thesis deserve consideration.
First, the REDEFINE-1 readout was numerically positive but did not clearly beat tirzepatide. CagriSema ~22.7% versus tirzepatide ~22.5% is essentially a tie. For a more complicated, two-drug combination, a tie may not be enough to justify the combination over single-drug tirzepatide.
Second, the added value of cagrilintide on top of semaglutide is less clear than the topline numbers suggest. If semaglutide alone in REDEFINE-1 produced higher weight loss than in earlier STEP trials, some of CagriSema's apparent benefit comes from the semaglutide component, not the cagrilintide addition. The incremental benefit of adding cagrilintide may be modest.
Third, side effect burden is higher with combination therapy. Two drugs, two side-effect profiles. Nausea rates appear higher in CagriSema than in semaglutide alone in the available data. Tolerability and adherence may be worse than with monotherapy.
Fourth, cost will be higher. A combination product typically prices above either component alone. Whether payers will support the higher price for the modest incremental benefit is uncertain.
Fifth, retatrutide (triple agonist) and orforglipron (oral GLP-1) are advancing on different mechanisms. CagriSema enters a competitive market segmenting on convenience and additional mechanisms, not just efficacy.
Decision framework for patients interested in amylin
If you are interested in cagrilintide specifically, the practical reality as of May 2026:
Cagrilintide is not available. You cannot legally access it in the United States. Gray-market suppliers are not legitimate sources and the products are not quality-tested.
Pramlintide (Symlin) is the only FDA-approved amylin analog. It is approved for diabetes management, not obesity. Off-label use for weight loss exists but is uncommon. The thrice-daily injection regimen is a significant adherence barrier.
If you are interested in the amylin pathway because you have not responded well to GLP-1 alone, discuss with your clinician whether other mechanism additions make sense. Bupropion-naltrexone (Contrave) operates through different pathways. Phentermine-topiramate (Qsymia) targets appetite through yet other mechanisms. None replicate amylin signaling specifically, but they offer mechanism diversification.
If you are waiting for CagriSema approval, plan for an uncertain timeline. The drug may approve in 2026-2027, may approve later, or may not be approved at all if Novo's regulatory strategy changes. Do not delay current therapy waiting for CagriSema unless you are stable and your clinical situation allows for waiting.
FAQ
What is cagrilintide?
Cagrilintide is an investigational long-acting amylin analog developed by Novo Nordisk. It binds amylin and calcitonin receptors to suppress appetite and slow gastric emptying. In phase 2 monotherapy at 2.4 mg weekly, cagrilintide produced approximately 10% weight loss (Lau et al., Lancet 2021). It is best known as part of the CagriSema combination with semaglutide. Cagrilintide is not FDA-approved as of May 2026.
Is cagrilintide a GLP-1?
No. Cagrilintide is an amylin analog, a separate class from GLP-1 agonists. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. It works on different receptors (amylin and calcitonin receptors) than GLP-1 receptor agonists. The mechanism is complementary to GLP-1 signaling, which is why cagrilintide is being studied in combination with semaglutide in the CagriSema program.
Who makes cagrilintide?
Cagrilintide is developed by Novo Nordisk, the same company that makes semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide (Saxenda, Victoza). Novo has built a portfolio of obesity and diabetes medications that includes both GLP-1 agonists and the amylin pathway. Cagrilintide is a longer-acting successor to pramlintide (Symlin), Novo's earlier amylin analog approved for diabetes.
What is CagriSema?
CagriSema is the combination of cagrilintide and semaglutide in a single weekly injection. Novo is developing it as a fixed-dose combination intended to deliver greater weight loss than either drug alone. The REDEFINE-1 phase 3 readout (late 2024) showed approximately 22.7% weight loss at 68 weeks. CagriSema is not FDA-approved as of May 2026.
How is cagrilintide different from pramlintide?
Pramlintide (Symlin) is an FDA-approved short-acting amylin analog used in type 1 diabetes. It must be injected before each meal (three times daily). Cagrilintide is a longer-acting amylin analog designed for once-weekly subcutaneous injection. Cagrilintide's structural modifications (including a fatty acid attachment similar to semaglutide's) extend its half-life dramatically. Cagrilintide is intended for weight management, not blood sugar control.
Is cagrilintide FDA-approved?
No. Cagrilintide is investigational as of May 2026. It is not FDA-approved as a standalone medication or as part of the CagriSema combination. FormBlends does not sell, supply, or compound cagrilintide. Patients seeking access through gray-market suppliers should be aware that those products are not quality-tested and are illegal in the United States.
What does cagrilintide do?
Cagrilintide produces three main effects through amylin receptor activation: slower gastric emptying (food stays in the stomach longer, prolonging satiety), enhanced satiety signaling to the brain (less appetite between meals), and suppression of post-meal glucagon (modest glucose effect). The net result is reduced caloric intake and weight loss over weeks to months. It complements GLP-1 signaling rather than duplicating it.
Sources
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. The Lancet. 2021;398:2160-2172.
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg. The Lancet. 2021;397:1736-1748.
- Novo Nordisk. REDEFINE-1 Phase 3 results, press release. December 2024.
- Hay DL, Chen S, Lutz TA, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews. 2015;67(3):564-600.
- U.S. Food and Drug Administration. Symlin (pramlintide acetate) Prescribing Information. 2005, revised.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384:989-1002. (STEP 1)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387:205-216. (SURMOUNT-1)
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity. NEJM. 2023;389:514-526.
- Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews. 2011;91(3):795-826.
- Novo Nordisk. Investor relations and pipeline updates. novonordisk.com.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes liraglutide trial. NEJM. 2015;373:11-22.
- Eli Lilly and Company. ACHIEVE-1 Phase 3 results for orforglipron. April 17, 2025.
Footer disclaimers
Platform Disclaimer. FormBlends provides physician-supervised weight management with FDA-approved and 503A-compounded GLP-1 medications. Cagrilintide and CagriSema are investigational and not part of our formulary. We do not have a commercial relationship with Novo Nordisk. This article is educational and does not constitute medical advice.
Compounded Medication Notice. Compounded semaglutide referenced in this article is prepared by licensed 503A pharmacies under individual prescription, where regulatory status allows. Compounded medications are not FDA-approved and not therapeutically interchangeable with branded Wegovy or Ozempic. Cagrilintide is not eligible for 503A compounding outside of compounding pharmacy actions that may not meet current FDA regulatory standards.
Results Disclaimer. Trial weight loss percentages cited are averages from published clinical studies. Individual outcomes vary substantially. Cross-trial comparisons (cagrilintide vs liraglutide vs semaglutide) are imperfect because of differences in trial design, duration, and patient populations.
Trademark Notice. Cagrilintide and CagriSema are development names for investigational compounds owned by Novo Nordisk A/S. Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, and Symlin are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation with Novo Nordisk or Eli Lilly.